Biopure
Biopure
Overview:
* Biopure Corporation is a privately owned biopharmaceutical firm specializing in the ultrapurification of proteins for human and veterinary use. * It is one of the three legitimate contenders in the emerging field of “blood substitutes”. * Their products Oxyglobin and Hemopure are blood substitutes for the animal and the human market respectively. * Oxyglobin has just received final FDA approval for commercial release and is ready for launch. Hemopure would soon enter Phase 3 clinical trials and was optimistically expected to see final FDA approval for release as a human substitute sometime in 1999.
Q.1. Should Biopure go ahead with launch of Oxyglobin or delay its release till Hemopure is ready for launch (after FDA's approval)? Please justify your choice on various factors.
Reasons FOR immediate launch of Oxyglobin: * Will have ‘first mover advantages’ of locking up key distributors and customers and gaining leadership. * There is currently a huge need for veterinary use (84% veterinary docs are dissatisfied with current available options). * If Hemopure fails to get final FDA approval, Biopure will have at least one profit making product in the market. * Will start making revenue immediately instead of sitting idle. * Will make the company more attractive since they already have a revenue generating product in the market. * Low manual cost, large capacity and no significant additional expenditure in developing the product any further will add on to the profitability. * No foreseeable competition in the near future (not at least for the next 2 years). * Will help Biopure gain valuable experience which is crucial in the launch of their star product – Hemopure. * An immediate launch will make people aware of the concept of blood substitutes. * Should cash in on the fact that it is the only blood substitute to get final FDA approval
Reasons FOR the launch of Oxyglobin AFTER Hemopure:
Overview:
* Biopure Corporation is a privately owned biopharmaceutical firm specializing in the ultrapurification of proteins for human and veterinary use. * It is one of the three legitimate contenders in the emerging field of “blood substitutes”. * Their products Oxyglobin and Hemopure are blood substitutes for the animal and the human market respectively. * Oxyglobin has just received final FDA approval for commercial release and is ready for launch. Hemopure would soon enter Phase 3 clinical trials and was optimistically expected to see final FDA approval for release as a human substitute sometime in 1999.
Q.1. Should Biopure go ahead with launch of Oxyglobin or delay its release till Hemopure is ready for launch (after FDA's approval)? Please justify your choice on various factors.
Reasons FOR immediate launch of Oxyglobin: * Will have ‘first mover advantages’ of locking up key distributors and customers and gaining leadership. * There is currently a huge need for veterinary use (84% veterinary docs are dissatisfied with current available options). * If Hemopure fails to get final FDA approval, Biopure will have at least one profit making product in the market. * Will start making revenue immediately instead of sitting idle. * Will make the company more attractive since they already have a revenue generating product in the market. * Low manual cost, large capacity and no significant additional expenditure in developing the product any further will add on to the profitability. * No foreseeable competition in the near future (not at least for the next 2 years). * Will help Biopure gain valuable experience which is crucial in the launch of their star product – Hemopure. * An immediate launch will make people aware of the concept of blood substitutes. * Should cash in on the fact that it is the only blood substitute to get final FDA approval
Reasons FOR the launch of Oxyglobin AFTER Hemopure: